JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $630
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on IDEXX Laboratories (NASDAQ:IDXX) and raises the price target from $600 to $630.
February 06, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Chris Schott reaffirmed an Overweight rating on IDEXX Laboratories and increased the price target from $600 to $630.
The upgrade in price target by a reputable analyst like Chris Schott from JP Morgan is a strong positive signal for IDEXX Laboratories. It suggests a bullish outlook on the stock, likely due to favorable business dynamics or financial performance that the analyst believes will drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100